Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fentanyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.80 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.80 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.80 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.80 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.80 |
| ▸ | DRD2 | P14416 | 1/20 | 0.80 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.80 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.80 |
| ▸ | MAOA | P21397 | 1/20 | 0.80 |
| ▸ | DRD4 | P21917 | 1/20 | 0.80 |
| ▸ | MAOB | P27338 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | HRH1 | P35367 | 1/20 | 0.80 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.80 |
| ▸ | DRD3 | P35462 | 1/20 | 0.80 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fentanyl SCHEMBL193602 | 1.00 | OPRM1 (0.80) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL40733 | 1.00 | OPRM1 (0.80) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL6002326 | 1.00 | OPRM1 (0.80) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL6908995 | 1.00 | OPRM1 (0.80) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL27481710 | 0.99 | OPRM1 (0.78) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL19066928 | 0.99 | OPRM1 (0.78) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL2722646 | 0.96 | OPRM1 (0.74) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL1773864 | 0.91 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL8804 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL916599 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346864-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | GALAPAGOS NV (BE) | 2013-03-06 | — | — | EP | claimed |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2024-07-23 | — | — | US | disclosed |
| EP-3976189-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2024-07-03 | — | — | EP | disclosed |
| US-12024511-B2 | Substituted imidazo[1,2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO., LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| EP-3867645-B1 | BIOMARKERS FOR A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DISEASE ACTIVITY IMMUNE INDEX THAT CHARACTERIZES DISEASE ACTIVITY | OKLAHOMA MED RES FOUND (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-112292129-B | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240124424-A1 | SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE | GALAPAGOS NV (BE) | 2024-04-18 | — | — | US | disclosed |
| US-20240108587-A1 | SYSTEMS COMPRISING A COMPOSITE BACKING AND METHODS FOR LONG TERM TRANSDERMAL ADMINISTRATION | CORIUM, LLC | 2024-04-04 | — | — | US | disclosed |
| CN-111433200-B | Compounds and pharmaceutical compositions for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20240091168-A1 | SYSTEMS AND METHODS FOR LONG TERM TRANSDERMAL ADMINISTRATION | CORIUM, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2002009707-A1 | FENTANYL COMPOSITION FOR NASAL ADMINISTRATION | NYCOMED DANMARK A/S (DK) | 2002-02-07 | — | — | WO | disclosed |
| US-20010037104-A1 | Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances | NUVO RESEARCH INC. (CA) | 2001-11-01 | — | — | US | disclosed |
| US-20010033858-A1 | Transdermal drug patch | ZARS, INC. | 2001-10-25 | — | — | US | disclosed |
| WO-2001064151-A1 | METHODS AND APPARATUS FOR CONTROLLED HEAT TO REGULATE TRANSDERMAL DELIVERY OF MEDICAL SUBSTANCES | ZHANG JIE (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064149-A1 | IMPROVED TRANSDERMAL DRUG PATCH | ZHANG JIE (US) | 2001-09-07 | — | — | WO | disclosed |
| US-6284266-B1 | TRANSDERMAL, HEATING THE SKIN WITH AN EXOTHERMIC REACTION | ZARS, INC. | 2001-09-04 | — | — | US | disclosed |
| EP-1117356-A1 | METHODS AND APPARATUS FOR IMPROVED ADMINISTRATION OF FENTANYL AND SUFENTANIL | Zars, Inc. (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000072868-A2 | PEPTIDES FOR THERAPEUTIC USE | PRENDERGAST PATRICK T (IE) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000018338-A1 | METHODS AND APPARATUS FOR IMPROVED ADMINISTRATION OF FENTANYL AND SUFENTANIL | ZARS, INC. (US) | 2000-04-06 | — | — | WO | disclosed |
| US-5851997-A | Use of human chorionic gonadotropin as an immune-potentiating antiviral agent | HARRIS PAMELA JO (US) | 1998-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024511-B2 | Substituted imidazo[1,2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | JAK1, JAK2, JAK3 | OPRM1 1346/4885OPRD1 2256/4885OPRK1 518/4885 |
| US-20240124424-A1 | SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE | COL2A1, COL1A1, COL14A1 | OPRM1 2155/4885OPRD1 2817/4885OPRK1 1867/4885 |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | OPRM1 4104/4885OPRD1 3307/4885OPRK1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.